Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
Ahmed Omar Kaseb,Elshad Hasanov,Hop Sanderson Tran Cao,Lianchun Xiao,Jean-Nicolas Vauthey,Sunyoung S. Lee,Betul Gok Yavuz,Yehia Mohamed,Aliya Qayyum,Sonali Jindai,Fei Duan,Sreyashi Basu,Shafini S. Yadav,Courtney Nicholas,Jing Jing Sun,Kanwat Pratap Singh Raghav,Asif Rashid,Kristen Carter,Yun Shin Chun,Ching-Wei David Tzeng,Divya Sakamuri,Li Xu,Ryan Sun,Vittorio Cristini,Laura Beretta,James C. Yao,Robert A. Wolff,James Patrick Allison,Padmanee Sharma
DOI: https://doi.org/10.1016/S2468-1253(21)00427-1
IF: 45.042
2022-01-01
The Lancet Gastroenterology & Hepatology
Abstract:Background Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed to evaluate the safety and tolerability of perioperative immunotherapy in resectable hepatocellular carcinoma. Methods In this single-centre, randomised, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma were randomly assigned (1:1) to receive 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery at 6 weeks) followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for 2 years, or 240 mg of nivolumab intravenously every 2 weeks (for up to three doses before surgery) plus one dose of 1 mg/kg of ipilimumab intravenously concurrently with the first preoperative dose of nivolumab, followed in the adjuvant phase by 480 mg of nivolumab intravenously every 4 weeks for up to 2 years plus 1 mg/kg of ipilimumab intravenously every 6 weeks for up to four cycles. Patients were randomly assigned to the treatment groups by use of block randomisation with a random block size. The primary endpoint was the safety and tolerability of nivolumab with or without ipilimumab. Secondary endpoints were the proportion of patients with an overall response, time to progression, and progression-free survival. This trial is registered with ClinicalTrials.gov (NCT03222076) and is completed. Findings Between Oct 30, 2017, and Dec 3, 2019, 30 patients were enrolled and 27 were randomly assigned: 13 to nivolumab and 14 to nivolumab plus ipilimumab. Grade 3-4 adverse events were higher with nivolumab plus ipilimumab (six [43%] of 14 patients) than with nivolumab alone (three [23%] of 13). The most common treatment related adverse events of any grade were increased alanine aminotransferase (three [23%] of 13 patients on nivolumab vs seven [50%] of 14 patients on nivolumab plus ipilimumab) and increased aspartate aminotransferase (three [23%] vs seven [50%]). No patients in either group had their surgery delayed due to grade 3 or worse adverse events. Seven of 27 patients had surgical cancellations, but none was due to treatment-related adverse events. Estimated median progression-free survival was 9middot4 months (95% CI 1middot47-not estimable [NE]) with nivolumab and 19middot53 months (2middot33-NE) with nivolumab plus ipilimumab (hazard ratio [HR] 0middot99, 95% CI 0middot31-2middot54); median time to progression was 9middot4 months (95% CI 1middot47-NE) in the nivolumab group and 19middot53 months (2middot33-NE) in the nivolumab plus ipilimumab group (HR 0middot89, 95% CI 0middot31-2middot54). In an exploratory analysis, three (23%) of 13 patients had an overall response with nivolumab monotherapy, versus none with nivolumab plus ipilimumab. Three (33%) of nine patients had a major pathological response (ie, >= 70% necrosis in the resected tumour area) with nivolumab monotherapy compared with three (27%) of 11 with nivolumab plus ipilimumab. Interpretation Perioperative nivolumab alone and nivolumab plus ipilimumab appears to be safe and feasible in patients with resectable hepatocellular carcinoma. Our findings support further studies of immunotherapy in the perioperative setting in hepatocellular carcinoma. Funding Bristol Myers Squibb and the US National Institutes of Health. Copyright Published by Elsevier Ltd.